Han Xiao, Guo Bo, Li Yongsheng, Zhu Bo
J Hematol Oncol. 2014 Aug 1;7:54. doi: 10.1186/s13045-014-0054-8.
The aberrant hemostasis is a common manifestation of cancer, and venous thromboembolism (VTE) is the second leading cause of cancer patients' mortality. Tissue factor (TF), comprising of a 47-kDa transmembrane protein that presents in subendothelial tissues and leukocytes and a soluble isoform, have distinct roles in the initiation of extrinsic coagulation cascade and thrombosis. Laboratory and clinical evidence showed the deviant expression of TF in several cancer systems and its tumor-promoting effects. TF contributes to myeloid cell recruitment in tumor stroma, thereby remodeling of tumor microenvironment. Additionally, the number of TF-positive-microparticles (TF+MP) from tumor origins correlates with the VTE rates in cancer patients. In this review, we summarize our current understanding of the TF regulation and roles in tumor progression and clinical complications.
异常止血是癌症的常见表现,静脉血栓栓塞(VTE)是癌症患者死亡的第二大主要原因。组织因子(TF)由一种存在于内皮下组织和白细胞中的47 kDa跨膜蛋白以及一种可溶性异构体组成,在启动外源性凝血级联反应和血栓形成中具有不同作用。实验室和临床证据表明TF在多种癌症系统中表达异常及其促肿瘤作用。TF有助于肿瘤基质中髓样细胞的募集,从而重塑肿瘤微环境。此外,来自肿瘤来源的TF阳性微粒(TF+MP)数量与癌症患者的VTE发生率相关。在本综述中,我们总结了目前对TF在肿瘤进展和临床并发症中的调节及作用的理解。